Format

Send to

Choose Destination
See comment in PubMed Commons below
ScientificWorldJournal. 2010 Mar 5;10:413-8. doi: 10.1100/tsw.2010.44.

Cucurbitacin: ancient compound shedding new light on cancer treatment.

Author information

  • 1Division of Hematology and Oncology, Cedars-Sinai Medical Center, School of Medicine, University of California, Los Angeles, CA, USA. hiromasa@ucla.edu

Abstract

Cucurbitacins and their derivatives are triterpenoids found in medicinal plants known for their diverse pharmacological and biological activities, including anticancer effects, throughout human history. Although initial attention to cucurbitacin as a potential anticancer drug withered for decades, recent discoveries showing that cucurbitacin is a strong STAT3 (Signal Transducers and Activators of Transcription-3) inhibitor have reclaimed the attention of the drug industry one more time. There is increasing evidence showing that some cucurbitacins not only inhibit the JAK-STAT pathway, but also affect other signaling pathways, such as the MAPK pathway, which are also known to be important for cancer cell proliferation and survival. Moreover, some reports have shown the synergistic effect of cucurbitacins with known chemotherapeutic agents, such as doxorubicin and gemcitabine. In this review, we will summarize the recent discoveries regarding molecular mechanisms of action of cucurbitacins in human cancer cells and discuss the possibilities of cucurbitacin as a future anticancer drug in clinical settings.

PMID:
20209387
DOI:
10.1100/tsw.2010.44
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation
    Loading ...
    Support Center